

17.US3.REG  
Ser. No. 09/826,509

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: Karin Lehmann-Bruinsma, et al.

Serial No.: 09/826,509


Group Art Unit: 1646

Filing Date: April 5, 2001

Examiner: R. Li

For: **NON-ENDOGENOUS, CONSTITUTIVELY  
ACTIVATED KNOWN G PROTEIN-  
COUPLED RECEPTORS**

DATE OF DEPOSIT: 02 FEB 2004  
I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS EXPRESS MAIL LABEL #EL963417526US,  
POSTAGE PREPAID ON THE DATE INDICATED ABOVE  
AND IS ADDRESSED TO THE COMMISSIONER FOR  
PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450



TYPED NAME: Michael A. Patané  
REGISTRATION NO: 42,982

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

**This Information Disclosure Statement is being filed as the submission of  
a concurrently filed Request for Continued Examination.**


**Fees**

- ☒ No Fee is owed by the applicant(s).
- ☐ The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

**Method of Payment of Fees**

- ☐ Attached is a check in the amount of \$\_\_\_\_\_. This form is submitted in duplicate.
- ☐ Charge Deposit Account No. 50-1275 in the amount of \$\_\_\_\_\_. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
- ☐ No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,




**Michael A. Patané**  
**Registration No. 42,982**

Dated: February 2, 2004

COZEN O'CONNOR, P.C.  
1900 Market Street, 5<sup>th</sup> Floor  
Philadelphia, PA 19103-3508  
(215) 665-6966 – Telephone  
(215) 665-2013 - Facsimile

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute Form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	09/826,509
Filing Date	April 5, 2001
First Named Inventor	K. Lehmann-Bruinsma
Group Art Unit	1646
Examiner Name	Ruixiang Li
Attorney Docket Number	17.US3.REG

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CL	BARR and MANNING, "Agonist-independent activation of Gz by the 5-hydroxytryptamine receptor co-expressed in Spodoptera frugiperda cells," J. Biol. Chem. (1997) 272:32979-32987.	
	CM	EGAN, et al., "Creation of a constitutively activated state of the 5-HT2A receptor site-directed mutagenesis: revelation of inverse agonist activity of antagonists," Ann. N.Y. Acad. Sci. (1998) 861:136-139.	
	CN	PAUWELS and WURCH, "Review: amino acid domains involved in constitutive activation of G-protein-coupled receptors," Mol. Neurobiol. (1998) 17:109-135.	
	CO	LEMBO and ALBERT, "Multiple phosphorylation sites are required for pathway-selective uncoupling of the 5-hydroxytryptamine1A receptor by protein kinase C," Mol Pharmacol. (1995) 48:1024-1029.	
	CP	MALMBERG and STRANGE, "Site-directed mutations in the third intracellular loop of the serotonin 5-HT1A receptor alter G protein coupling from Gi to Gs in a ligand-dependent manner," J. Neurobiol. (2000) 75:1283-1293.	
	CQ	KAWANISHI, et al., "Novel mutations in the promoter and coding region of the human 5-HT1A receptor gene and association analysis in schizophrenia," Am. J. Med. Genet. (1998) 81:434-439.	
		International Search Report, July 10, 2002.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.